Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia  

作　　者：Danni Xie Bing Wang Xue Bai Xin Jin Wenyi Lu Meng Zhang Yi Zhang Xinping Cao Mingfeng Zhao 

机构地区：[1]First Central Clinical College,Tianjin Medical University,Tianjin 300110,China [2]Department of Hematology,Tianjin First Central Hospital,Tianjin 300192,China [3]Liangzhu Laboratory,Zhejiang University Medical Center,Hangzhou,Zhejiang 310011,China

出　　处：《Chinese Medical Journal》2025年第1期114-116,共3页中华医学杂志(英文版)

基　　金：supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030);the Key Projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018);the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B);the Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820);the Tianjin Health Research Project(No.TJWJ2023QN027);the Tianjin Health Bureau Project(No.ZC20074);the Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010).

摘　　要：To the Editor:Chimeric antigen receptor(CAR)-T-cell therapy has made considerable breakthroughs in the treatment of lymphoma and myeloma,but the lack of suitable or specific targets for acute myelocytic leukemia(AML)has limited the progress of CAR-T-cell therapy in the clinical treatment of AML.Cluster of differentiation(CD)312,a member of the adhesion G protein-coupled receptor family,is highly expressed in acute myeloid leukemia and absent in normal hematopoietic stem cells(HSCs),[1]making it a potential target antigen for CART-cell therapy.In this study,we assessed the expression of CD312 in AML cell lines and patients and constructed anti-CD312 CAR-T cells,which showed excellent antitumor activity and safety in vitro and in vivo.Notably,CD312 CAR-T cells exhibited no significant off-target effects,suggesting their potential as an effective and safe treatment strategy for AML.

关 键 词：CAR T Cell Therapy Hematopoietic Stem Cells Target Antigen hematopoietic stem cells hscs making Acute Myeloid Leukemia Chimeric Antigen Receptor T Cells 

分 类 号：R733.71[医药卫生—肿瘤]